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esponsibility of InstAbstract In antiviral therapy of hepatitis B virus (HBV) infection, drug resistance remains a huge
obstacle to the long-term effectiveness of nucleoside/tide analogs (NAs). Primary resistance mutation
(rtM204V) contributes to lamivudine (LAM)-resistance, and compensatory mutations (rtL180M and
rtV173L) restore viral ﬁtness and increase replication efﬁciency. The evaluation of new anti-viral agents
against drug-resistant HBV is limited by the lack of available small-animal models. We established LAM-
resistance HBV replication mice models based on clinical LAM-resistant HBV mutants. Double
(rtM204VþrtL180M) or triple (rtM204VþrtL180MþrtV173L) lamivudine-resistant mutations were
introduced into HBV expression vector, followed by hydrodynamic injection into tail vein of NOD/
SCID mice. Viremia was detected on days 5, 9, 13 and 17 and liver HBV DNA was detected on day 17
after injection. The serum and liver HBV DNA levels in LAM-resistant model carrying triple mutations
are the highest among the models. Two NAs, LAM and entecavir (ETV), were used to test the availability
of the models. LAM and ETV inhibited viral replication on wild-type model. LAM was no longer
effective on LAM-resistant models, but ETV retains a strong activity. Therefore, these models can be used
to evaluate anti-viral agents against lamivudine-resistance, affording new opportunities to establish other
drug-resistant HBV small-animal models.
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Hepatitis B virus (HBV) is the prototype member of the
hepadnavirus family, which is a group of the smallest DNA-
containing enveloped animal viruses known. HBV infection is
the leading cause of chronic hepatitis, cirrhosis and hepatocel-
lular carcinoma (HCC)1–4. It is estimated that approximately 350
million people worldwide are chronic HBV carriers and
15%–40% of them eventually develop HBV-related cirrhosis or
HCC5–8. Around one million deaths per year are due to HBV-
related liver pathologies9,10. There are two classes of drugs
available for the treatment of chronic HBV infection: ﬁrst is the
immune modulator interferon-α (standard or pegylated (PEG)-
IFN-α), second are nucleoside or nucleotide analogs (NAs),
which act as the HBV polymerase inhibitors, such as lamivudine
(LAM), entecavir (ETV), tenofovir disoproxil fumarate (TDF),
etc. IFN-α monotherapy has been the standard of treatment for
chronic hepatitis B since the middle 1990s11, but it is poorly
tolerated and effective, only effective in 20%–40% patients. With
the introduction of LAM, several oral HBV polymerase inhibitors
were approved and accounted for the vast majority of therapies
for chronic hepatitis B due to higher tolerance and more
convenient administration, which reduced the occurrence of
HCC and liver cirrhosis12. However, drug resistance resulting
from HBV polymerase mutations with the NAs treatment is a
huge obstacle to successful anti-viral therapy. Clinically, along
with long-term LAM treatment, the emergence of lamivudine-
resistant HBV was discovered in approximately 24% of patients
after 1 year of therapy and in 70% after 5 years of therapy, so it
was no longer considered a ﬁrst-line agent in treatment of chronic
HBV infection13. Therefore, it is important for designing and
exploring new anti-viral agents to understand the mechanism of
HBV drug resistance and avoid it.
To date, there are several animal models being described
previously for studying the mechanism of HBV infection and
exploring new anti-viral agents, but the evaluation of new anti-
viral agents against drug-resistant HBV is limited by the lack of
available small-animal models. Here we describe recently developed
drug-resistant HBV mice models that alleviate many experimental
constraints. Adapting the hydrodynamic-based procedure, we estab-
lished convenient and replication-competent drug-resistant HBV
NOD/SCID mice models based on clinic LAM-resistant mutants
and evaluated the availability of these models in the assessment of
anti-viral drugs14.2. Materials and methods
2.1. Reagents and animals
Female NOD/SCID mice at 6–9 weeks of age were purchased
from Vital River Laboratory Animal Technology Co., Ltd.,
Beijing, China. Animals were bred and cared under speciﬁc
pathogen-free conditions in the Experimental Animal Center of
the Institute of Medicinal Biotechnology, Chinese Academy of
Medical Sciences. Our studies on mice were carried out in strict
accordance with the recommendations in the Code of Ethics of the
World Medical Association.
Lamivudine (LAM) and entecavir (ETV) tablets were purchased
from GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. and
Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.,
respectively.2.2. Construction of lamivudine-resistant mutations
pTmcs-HBV1.3 and the Sleeping Beauty transposase expression
plasmid (pCMV-SB) were generously provided by F.V. Chisari's
laboratory. pTmcs-HBV1.3 is an HBV replication-competent plas-
mid, which encodes a wild-type, terminally redundant (1.3-unit-
length) HBV genome (Genbank accession number V01460). The
supergenomic DNA was ﬂanked by the inverted repeat (IR)
recognition sequences of the Sleeping Beauty transposase. pTmcs-
HBV1.3-3TCR and pTmcs-HBV1.3-3TCR-V173L are two different
lamivudine-resistant mutants carrying rtL180M–rtM204V double
mutations and rtL180M–rtM204V–rtV173L triple mutations,
respectively. For their generations, rtL180M, rtM204V and rtV173L
mutations were introduced into pTmcs-HBV1.3 by site-mutagenesis
with the appropriate primers using QuickChanges Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies) as per the
manufacturer's recommendations. The primer pairs of
50–TTGGCTTTCAGTTATGTGGATGATGTGGTATTG–30 and
50–CAATACCACATCATCCACATAACTGAAAGCCAA–30 were
for rtM204V mutation, 50–GTGGGCCTCAGCCCGTTTCTCATG-
GCTCAGTTTACTAGTGCC–30 and 50–GGCACTAGTAAACTGA-
GCCATGAGAAACGGGCTGAGGCCCAC–30 were for rtL180M
mutation, 50–AAAATTCCTATGGGATTGGGCCTCAGCCCG-
TTT–30 and 50–AAACGGGCTGAGGCCCAATCCCATAGGAA-
TTTT–30 were for rtV173L mutation. All constructs were sequenced
to conﬁrm that no additional mutations had been introduced.
2.3. Hydrodynamic injection of plasmid
The method of hydrodynamic injection of plasmids has been
previously described15. In brief, a total of 13.5 μg of pTmcs-
HBV1.3, pTmcs-HBV1.3-3TCR or pTmcs-HBV1.3-3TCR-V173L
and 4.5 μg of pCMV-SB were co-injected into the tail vein of 6- to
9-week-old NOD/SCID mice in a volume of saline equivalent to
8% of the mouse body weight (e.g., 1.6 mL for mouse of 20 g).
The total volume was delivered within 5–8 s. The mouse serum
samples were taken from the retro-orbital vessels on day 5 after
injection to measure the HBV surface antigen (HBsAg) level by
using the Diagnostic Kit for Hepatitis B Virus Surface Antigen
(ELISA) (Shanghai Kehua Bio-Engineering) according to the
manufacturer's instructions. HBsAg/Cut-off value in serum serves
as an estimate of transfection efﬁciency in these experiments.
2.4. Evaluation of the availability of mouse models
The HBsAg-positive mice were randomly divided into three groups
with 10 mice each on day 5 after hydrodynamic injection. Brieﬂy,
LAM (20 mg/kg) and ETV (0.1 mg/kg) were given twice per day by
oral gavage administration in a medication course lasting 12 days, and
the equivalent volume of saline was used as a control. To assess the
efﬁcacies of LAM and ETV against HBV replication, the mouse serum
samples were collected every four days after drug administration. On
the last day, the mice were sacriﬁced and the liver tissues were
harvested and stored at 70 1C until assayed.
2.5. Quantitation of HBV DNA in mouse sera
The mouse serum samples were collected on days 0, 4, 8 and 12
after drug administration, and the method of purifying encapsi-
dated viral DNA has been previously described15. Brieﬂy, 50 μL
of isolated serum was ﬁrst digested with DNase I to eliminate
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Buffer; incubated at 37 1C for 12–16 h). The encapsidated viral
DNA was then released by proteinase K digestion (20 mmol/L
EDTA/1% SDS/400 units proteinase K; incubated at 37 1C for
12 h), followed by extraction with 500 μL of Tris-saturated-
phenol and precipitated with 1 mL cold ethanol. After centrifu-
gation at 12,000 rpm for 10 min, precipitates were again resus-
pended in 50 μL of double-distilled H2O and stored at 20 1C.
Serum HBV DNA levels were quantiﬁed in 20 μL reaction
system by a real-time polymerase chain reaction (PCR, see
below).
2.6. Quantitation of HBV DNA and input DNA in mouse livers
Total genomic DNA was puriﬁed from 15 mg of liver tissues using
the DNeasys mini kit (QIAGEN) as per the manufacturer's
recommendations. Brieﬂy, the puriﬁed DNA was eluted with
50 μL of double-distilled H2O, then its concentration was mea-
sured with NanoDrop 2000 (Thermo Scientiﬁc) and stored at
20 1C. HBV DNA and input vector copy numbers were
measured by real-time PCR in a 20 μL reaction mixture containing
50 ng of liver genomic DNA (see below). An excess 42-fold of
HBV over input plasmid was interpreted as evidence that active
replication was ongoing in the liver.
2.7. Real-time PCR
HBV DNA and input vector copy numbers were determined by real-
time PCR in 20 μL reaction system in Power SYBRs Green PCR
Master Mix (Applied Biosystems), using an Applied Biosystems 7500
fast real-time thermocycler (Applied Biosystems). Thermal cycling
parameters consisted of 10 min denaturation step at 95 1C, followed by
40 cycles of denaturation (15 s at 95 1C) and annealing/extension (60 s
at 60 1C). A series of plasmid pTmcs-HBV1.3 diluted to 108, 107, 106,
105, 104, 103 and 102 copies per reaction with 0.5 ng/μL human
genomic DNA was used as standard. All samples were analyzed in
triplicate. The PCR primers used to amplify each respective amplicon
were: HBV DNA primers HBV 469-488F (50–CCCGTTTG-
TCCTCTAATTCC–30) and HBV 588-569R (50–GTCCGAAGGTT-
TG;GTACAGC–30), input vector pTHBV-5585U20 (50–CCAG-
TCGGGAAACCTGTCGT–30) and pTHBV-5675L20 (50–GCAGC-
GAGTCAGTGAGCGAG–30)16. pTHBV-5585U20 and pTHBV-
5675L20 annealed to sequences within the Sleeping Beauty transposase
IR sequences in the plasmid backbone of vector pTmcs.
2.8. Statistical analysis
Bar graphs were plotted to show mean7standard deviation (SD)
and statistical analyses were performed. A P value ofo0.05 in the
Student's t-test was considered statistically signiﬁcant.3. Results
3.1. Introducing the drug-resistant HBV replicative plasmid into
NOD/SCID mice leads to viral gene expression in vivo
The application of NAs is hampered by the appearance of
drug-resistant HBV. Thus, it is essential to understand the
mechanism of resistance to HBV polymerase inhibitors in
long-term treatment strategy. Yang et al.15,17 previouslydescribed a mouse model supporting HBV gene expression
and replication in the liver of NOD/SCID mice through
hydrodynamic injection, which introduced an 1.3-fold HBV
DNA (pTmcs-HBV1.3) and Sleeping Beauty transposase
(pCMV-SB) into the tail vein of mice. Taking advantage of
the hydrodynamic-based procedure, we established two LAM-
resistant HBV replication mouse models by injecting pTmcs-
HBV1.3-3TCR and pTmcs-HBV1.3-3TCR-V173L, respec-
tively, into NOD/SCID mice to transfect hepatocytes in vivo.
On day 5 after injection, the percentage of HBsAg-positive
with injection of pTmcs-HBV1.3, pTmcs-HBV1.3-3TCR and
pTmcs-HBV1.3-3TCR-V173L were 95.24%, 100% and 100%,
respectively (Fig. 1A) and the viremia were 49.2 106,
7.9 106, and 5.8 106 copies/mL, respectively (Fig. 1B).
As show in Fig. 1C, HBV DNA levels were more than 2-
fold higher in mouse liver compared to their own input vector
level. These results indicated that hydrodynamic injection of
the drug-resistant HBV replicative plasmids leads to viral gene
expression in vivo.
3.2. Viremia of wild-type and LAM-resistant mouse models
For a successful experimental animal model of HBV infection, high
level and long life-span viremia are important15. Fig. 1B shows the
viremia of three HBV replication mouse models. On day 5 after
injection, the viral replication in wild-type mouse serum is the highest
among three models; HBV DNA copy numbers of LAM-resistant
viruses carrying double or triple mutations were 16.1% and 11.8% of
wild-type virus, respectively. It is interesting that viral replication
gradually decreased with time in one of the LAM-resistant models
(double mutants) and HBV DNA copy numbers were 3.52 104
copies/mL on day 17 after injection of pTmcs-HBV1.3-3TCR.
However, in another LAM-resistant model (triple mutants), the level
reached the peak on day 9 after injection of pTmcs-HBV1.3-3TCR-
V173L and the decrease speed was slower than the wild-type model.
The copy numbers are 116.5 106 and 65.0 106 copies/mL on day
9 and 17 after injection of pTmcs-HBV1.3-3TCR-V173L. Taken
together, serum viral level and sustained time were different among the
three models, with pTmcs-HBV1.3-3TCR-V173L displaying the
superiority.
3.3. Replication ability of wild-type and LAM-resistant HBV
DNA in mouse liver
To investigate the replication ability of liver HBV DNA in wild-
type and LAM-resistant HBV mouse models, the mice were
sacriﬁced and the liver tissues were harvested on day 17 after
injection. Total genomic DNA was extracted from liver tissues
and HBV DNA levels were measured. As shown in Fig. 1D,
compared with wild-type mouse model, viral replication
decreases about 10.06-fold in the rtL180M–rtM204V double
mutants, but increases about 7.79-fold in the rtL180M–
rtM204V–rtV173L triple mutants. The HBV DNA copy numbers
were 24.5 106 copies/mL in wild-type mouse liver, and the
values in LAM-resistant mouse livers carrying double or triple
mutations were 2.4 106 and 191.3 106 copies/mL, respec-
tively (Fig. 1D), suggesting that rtM204V and rtL180M double
mutations in LAM-resistant HBV mutants resulted in the decline
of replication ability, but the third compensatory rtV173L
mutation signiﬁcantly increased the HBV replication ability
in vivo.
Figure 1 Viremia and viral gene expression in the livers after hydrodynamic transfection with different DNA. (A) The mice sera were isolated on
day 5 after injection to measure the HBV surface antigen (HBsAg) level. HBsAg/Cut-off value in serum serves as an estimate of transfection
efﬁciency in these experiments. HBsAg/Cut-off value greater than 1 was HBsAg-positive. HBsAg-positive NOD/SCID mice were qualiﬁed for the
next experiment. (B) HBV DNA was puriﬁed from serum on days 5, 9, 13 and 17 after injection and analyzed for kinetics of viremia by real-time
PCR. (C) HBV DNA was puriﬁed from the liver on day 17 after injection. Ratios of HBV/Input vectors greater than 2 veriﬁed active viral
replication in mouse liver. (D) HBV DNA was puriﬁed from the liver on day 17 after injection. The copies of Liver HBV DNA and input vector
were detected by real-time PCR.
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the anti-viral drugs
To verify whether the HBV replication mouse models can be used for
the evaluation of anti-HBV agents, we used two nucleotide analogs,
LAM and ETV, to test the availability of these models. Our results
showed that both LAM and ETV could decrease HBV DNA level in
wild-type mouse serum and liver. In serum, the HBV levels in LAM-
and ETV-treated groups signiﬁcantly decreased by 54.34% and
99.96%, respectively, compared with negative control on day 12
after treatment. In liver, the HBV levels in LAM- and ETV-treated
groups signiﬁcantly decreased by 43.04% and 97.47%, respectively
(Figs. 2A and 3A). Furthermore, as shown in Figs. 2B, 2C, 3B and
3C, in two LAM-resistant mouse models, LAM cannot decrease
serum and liver HBV level signiﬁcantly on day 12 after ETV
treatment, but ETV retains strong efﬁcacy in the liver with the
inhibition rates of 87.18% and 84.22% in double and triple mutants,
respectively, compared with negative control. Although ETV
decreased the serum HBV level signiﬁcantly in triple mutants,
ETV no longer had its strong efﬁcacy in serum HBV DNA level
in double mutants (Fig. 2B), which may be due to the decrease
of HBV replication efﬁciency in double mutants. These results
indicated that LAM-resistant HBV mouse models, especially triple
mutations, were established successfully and can be used to evaluate
the efﬁcacy of anti-viral compounds against drug-resistant HBV
infection.4. Discussion
Hepatitis B virus (HBV) belongs to the Hepadnaviridae family,
which includes human HBV, other mammalian viruses such as the
woodchuck hepatitis virus (WHV), the ground squirrel hepatitis
virus (GSHV), the artic squirrel hepatitis virus (ASHV) and the
woolly monkey hepatitis virus (WMHV), and avian viruses such
as duck hepatitis B virus (DHBV), the heron hepatitis virus (HHV)
and snow goose hepatitis virus (SGHV)18–23. There are several
animal models such as DHBV, WHV, HBV-infected chimpanzees
and HBV transgenic mice, offering opportunities for in vivo
studies of the mechanism of genome replication, viral persistence
and disease pathogenesis21,22,24,25, and they have assisted the
discovery of new antiviral drugs. Yang and his colleagues15
established a more ideal and convenient mouse model by introdu-
cing the HBV DNA to the livers of immunocompetent mice based
on the hydrodynamic transfection method.
However, the evaluation of new anti-viral agents against drug-
resistant HBV is limited by the lack of available small-animal
models. Along with long-term NA treatment, the emergence of
drug-resistant HBV was a huge problem. Clinically, the LAM-
resistant viral mutations are rtL180M–rtM204V in HBV polymer-
ase. Moreover, rtV173L was invariably found as a third compen-
satory mutation in conjunction with rtM204V and rtL180M in one
of three patients who failed in lamivudine therapy26, and it was
not observed as a single change in chronic hepatitis B patients27.
Figure 3 The effect of two NAs on liver HBV DNA on day 12 after treatment in three different mouse models. (A) In wild-type HBV (pTmcs-
HBV1.3) transfection mouse liver, the HBV levels in LAM and ETV-treated groups were signiﬁcantly decreased by 43.04% and 97.47%,
respectively, compared with negative control on day 12 after treatment. (B) In double-mutant HBV (pTmcs-HBV1.3-3TCR) transfection mouse
liver, LAM did not decrease HBV level signiﬁcantly; ETV retained efﬁcacy in the liver, the inhibition rate is 87.18%. (C) In triple mutant HBV
(pTmcs-HBV1.3-3TCR-V173L) transfection mouse liver, LAM also did not decrease the HBV level; ETV displayed strong efﬁcacy, the inhibition
rate is 84.22%. nPo0.05, nnPo0.01 vs. wild-type HBV (pTmcs-HBV1.3) transfection mouse.
Figure 2 The effect of two NAs on serum HBV DNA on days 0, 4, 8 and 12 after drug treatment in three different mouse models. (A) In wild-
type HBV (pTmcs-HBV1.3) transfection mouse serum, the HBV levels in LAM and ETV-treated groups were signiﬁcantly decreased by 54.34%
and 99.96%, respectively, compared with negative control on day 12 after treatment. (B) In double mutant HBV (pTmcs-HBV1.3-3TCR)
transfection mouse serum, the HBV levels declined rapidly. Low viral titers concealed the efﬁcacy of ETV. (C) In triple mutant HBV (pTmcs-
HBV1.3-3TCR-V173L) transfection mouse serum, the viral replication sustained high level; LAM did not decrease serum HBV level; ETV
displayed strong efﬁcacy, the inhibition rate was 92.30% on day 12 after ETV treatment.
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LAM-resistant data, we successfully established the LAM-resistant
mouse models by introducing HBV DNA carrying double or triple
LAM-resistant mutations into the tail vein of NOD/SCID mice,
which is lack of functional T/B cells and beneﬁcial to viral
persistent replication.
Two NAs targeting viral polymerase, LAM and ETV, are used
for the HBV treatment. In long-term monotherapy, they are
associated with the emergence of drug-resistant mutations in the
RT domain of the polymerase28,29. Viral drug-resistant sites are
different between LAM and ETV. When treating with LAM, drug
resistance arises rapidly and amino acid substitutions compromise
rtM204V/I, rtL180M and rtV173L, etc. When treating with ETV,
drug resistance arises less rapidly, amino acid substitutions
compromise rtS202I, rtT184G and rtI169T, etc. They do not share
cross-resistance. Moreover, ETV can be used for the treatment of
LAM-resistant HBV patients in clinic.
In our experiment, rtL180M–rtM204V double mutations
reduced HBV replication capacity in vivo compared with wild-
type HBV. In serum, the decreased values were 95.86%, 99.94%
and 99.79% on days 5, 9 and 17 after injection, respectively. In the
liver, the decreased value was 90.96% on day 17 after injection.
These results are consistent with Delaney's observation26. In
rtL180M–rtM204V double mutations HBV mouse model, lowviral titer partially concealed the efﬁcacy of ETV in serum,
although ETV displayed efﬁcacy in the liver (Figs. 2B and 3B).
As illustrated in Fig. 4, rtM204V/I are primary resistance mutations
which mapped in conserved YMDD motif within C domain of the
viral RT and facilitate ongoing viral DNA synthesis in the presence of
LAM. The compensatory mutations include rtL180M and rtV173L
within the B domain that restore viral ﬁtness. In Delaney's observation,
the rtL180M–rtM204V double mutations can reduce HBV replication
in vitro compared with wild-type HBV, but the addition of rtV173L
mutation to LAM-resistant HBV can increase HBV replication. As
illustrated in Fig. 1B and 1D, the replication of rtL180M–rtM204V–
rtV173L triple mutant increased compared to wild-type HBV construct
and double mutant in NOD/SCID mice.
We evaluated the availability of the mouse models through the
application of nucleotide analogs. LAM and ETV are all effective
in wild-type models (Figs. 2A and 3A), but the models carrying
the double or triple mutations were highly resistant to LAM
(Figs. 2B and 3B). Sherman and colleagues30 found that ETV was
less potent in LAM-resistant patients. Despite an increased dose of
1 mg/kg, only 19% and 40% of these patients achieved undetect-
able HBV DNA after one and two years, respectively. For the level
of serum HBV DNA, we observed the same results in LAM-
resistant models carrying double mutations. However, ETV
remains potent on the model carrying triple mutations, which
Figure 4 HBV polymerase gene and drug-resistant mutation29. The locations of LAM resistance mutations in HBV polymerase (Pol) open
reading frame (ORF) are shown. HBV Pol comprises four regions: terminal protein (TP), spacer, reverse transcription region (Pol/RT) for viral
HBV replication and RNaseH region. RT region is divided into 7 domains (A–G). The conserved motif of tyrosine, methionine, aspartate and
aspartate (YMDD) locates in C domain. HBsAg ORF overlaps RT domain. LAM resistance arises rapidly; amino acid substitutions include
rtM204V/I, rtL180M and rtV173L, etc. ETV resistance arises less rapidly; amino acid substitutions include rtS202I, rtT184G, rtI169T, etc.
Drug-resistant HBV small-animal models 275may be due to the enhancement of the viral replication caused by
the third compensatory mutation rtV173L. We also observed that
ETV signiﬁcantly decreased the level of HBV DNA in LAM-
resistant (double and triple mutants) mouse liver compared to the
saline control (Fig. 3B and 3C).
Based on our data, we conﬁrmed that the wild-type and LAM-
resistant HBV replication mouse models were established success-
fully in our laboratory. These models can afford new opportunities
for further understanding of the molecular mechanism of genome
replication, viral persistence and drug resistance. More impor-
tantly, they may play an important role in discovering new agents
against HBV mutants and developing a new mouse model of other
drug resistance.Acknowledgments
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